Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

SIMPLE SUMMARY: One of the reasons for treatment resistance of PDAC is the desmoplastic reaction initiating the production of large amounts of tumor stroma. LDE225 is a pharmacological Hedgehog signaling pathway inhibitor and is thought to specifically target tumor stroma. LDE225 in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: Pijnappel, Esther N., Wassenaar, Nienke P. M., Gurney-Champion, Oliver J., Klaassen, Remy, van der Lee, Koen, Pleunis-van Empel, Marjolein C. H., Richel, Dick J., Legdeur, Marie C., Nederveen, Aart J., van Laarhoven, Hanneke W. M., Wilmink, Johanna W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507646/
https://www.ncbi.nlm.nih.gov/pubmed/34638351
http://dx.doi.org/10.3390/cancers13194869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507646/
https://www.ncbi.nlm.nih.gov/pubmed/34638351
http://dx.doi.org/10.3390/cancers13194869

Ejemplares similares